Prognostic role of microRNA-155 in patients with leukemia: A meta-analysis

Zhang, Xiaoyu; Wang, Yong; Guo, Qiang; Diao, Yutao; Liu, Hongyan; Song, Guanhua; Wang, Wei; Zhang, Zhiyong; Yin, Hui; Li, Lianlian

doi:10.1016/j.cca.2018.04.015

Cited by 13 publications

(7 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 In a recent meta-analysis, Zhang et al 15 found that miR-155 expression was associated with lower overall survival for leukemia patients, and concluded that it may be a promising prognostic biomarker for this patient population. One previous study performed on transgenic mice found that overexpression of miR-155 causes a lymphoproliferative disease resembling the human diseases, which suggests that miR-155 is involved in the pathogenesis of ALL and high-grade lymphoma, 13 miRNAs regulate expression of mRNA posttranscriptionally and influence the direction of lymphoid precursor maturation in specific stages of lymphopoiesis.…”

Section: Discussionmentioning

confidence: 99%

“…This was in agreement with our results; we found miR-155a to have significant expression levels in highrisk ALL patients. Studies done by Ward et al 1 have shown that miR-181 acts as a tumor suppressor in the pathogenesis of AML and was significantly correlated to the survival of patients with AML, an earlier report by Zhang et al 15 has also proven that downregulation of miR-181a expression was associated with poor prognosis in patients with cytogenetically abnormal acute myeloid leukemia (AML). The data on the link between miR-181a and ALL high-risk characteristics is scarce and needs further research, our results could not establish a significant relationship between miR-181a and high-risk ALL patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

miRNA‐155 and miRNA‐181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia

El‐Khazragy

Noshi

Abdel-Malak

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Mortality rates of acute lymphoblastic leukemia (ALL) have improved over the past 20 years; however, a significant portion of deaths stems from the lack of prognostic biomarkers, which can direct therapy and overcome drug resistance. microRNA‐155a (miRNA‐155a) and miRNA‐181a are two single‐stranded miRNAs involved in the pathogenesis of many types of leukemia and lymphoma and is linked to drug resistance. We investigated their expression levels in 55 patients, 45 diagnosed with ALL and 10 as a control group. We found that miRNA‐155a and miRNA‐181a were significantly upregulated in the ALL group with both being linked to high levels of minimal residual disease and poor prognosis. miRNA‐155a cutoff value was significant in discriminating between high‐ and low‐risk ALL patients as well as between ALL patients and healthy controls, miRNA‐181a cutoff value, however, was not significant. Both markers levels were significantly downregulated after therapy. We conclude that miR‐155 is correlated with poor prognosis in ALL, whereas we couldn’t link miRNA‐181a to the prognosis in ALL. Moreover, the marked decrease in their expression after therapy could reflect their impact on disease outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

miRNA‐155 and miRNA‐181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia

El‐Khazragy

Noshi

Abdel-Malak

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Several miRNAs have been studied for their diagnostic, prognostic or therapeutic potential [ 73 ]. Results of a meta-analysis of miR-155 and its role in overall survival of AML and CLL patients indicate that high miR-155 expression is associated with lower overall survival of patients, making it a promising prognostic biomarker [ 74 ]. Six miRNAs were identified to have potential diagnostic and prognostic uses for AML.…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs in Leukemias: A Clinically Annotated Compendium

Turk

Calin

Kunej

2022

IJMS

View full text Add to dashboard Cite

Leukemias are a group of malignancies of the blood and bone marrow. Multiple types of leukemia are known, however reliable treatments have not been developed for most leukemia types. Furthermore, even relatively reliable treatments can result in relapses. MicroRNAs (miRNAs) are a class of short, noncoding RNAs responsible for epigenetic regulation of gene expression and have been proposed as a source of potential novel therapeutic targets for leukemias. In order to identify central miRNAs for leukemia, we conducted data synthesis using two databases: miRTarBase and DISNOR. A total of 137 unique miRNAs associated with 16 types of leukemia were retrieved from miRTarBase and 86 protein-coding genes associated with leukemia were retrieved from the DISNOR database. Based on these data, we formed a visual network of 248 miRNA-target interactions (MTI) between leukemia-associated genes and miRNAs associated with ≥4 leukemia types. We then manually reviewed the literature describing these 248 MTIs for interactions identified in leukemia studies. This manually curated data was then used to visualize a network of 64 MTIs identified in leukemia patients, cell lines and animal models. We also formed a visual network of miRNA-leukemia associations. Finally, we compiled leukemia clinical trials from the ClinicalTrials database. miRNAs with the highest number of MTIs were miR-125b-5p, miR-155-5p, miR-181a-5p and miR-19a-3p, while target genes with the highest number of MTIs were TP53, BCL2, KIT, ATM, RUNX1 and ABL1. The analysis of 248 MTIs revealed a large, highly interconnected network. Additionally, a large MTI subnetwork was present in the network visualized from manually reviewed data. The interconnectedness of the MTI subnetwork suggests that certain miRNAs represent central disease molecules for multiple leukemia types. Additional studies on miRNAs, their target genes and associated biological pathways are required to elucidate the therapeutic potential of miRNAs in leukemia.

show abstract

“…In non-small-cell lung cell carcinoma, the effect of miR-155 expression on patient survival was dependent on the histological subtype, with negative effects of increased miR-155 expression in adenocarcinoma and decreased miR-155 expression in squamous cell carcinoma [43]. However, in general, increased miR-155 expression is associated with worsened survival in tumor patients, as seen in pancreatic ductal adenocarcinoma [6], colorectal carcinoma [44], hepatocellular carcinoma [45], breast cancer [46], glioma [47], osteosarcoma [13], or leukemia [48].…”

Section: Discussionmentioning

confidence: 99%

MiR-155-5p and MiR-203a-3p Are Prognostic Factors in Soft Tissue Sarcoma

Greither

Koser

Holzhausen

et al. 2020

Cancers

View full text Add to dashboard Cite

Soft tissue sarcoma (STS) is a heterogeneous group of rare malignancies with a five-year survival rate of approximately 50%. Reliable molecular markers for risk stratification and subsequent therapy management are still needed. Therefore, we analyzed the prognostic potential of miR-155-5p and miR-203a-3p expression in a cohort of 79 STS patients. MiR-155-5p and miR-203a-3p expression was measured from tumor total RNA by qPCR and correlated with the demographic, clinicopathological, and prognostic data of the patients. Elevated miR-155-5p expression was significantly associated with increased tumor stage and hypoxia-associated mRNA/protein expression. High miR-155-5p expression and low miR-203a-3p expression, as well as a combination of high miR-155-5p and low miR-203a-3p expression, were significantly associated with poor disease-specific survival in STS patients in the Kaplan–Meier survival analyses (p = 0.027, p = 0.001 and p = 0.0003, respectively) and in the univariate Cox regression analyses (RR = 1.96; p = 0.031; RR = 2.59; p = 0.002 and RR = 4.76; p = 0.001, respectively), but not in the multivariate Cox regression analyses. In conclusion, the oncomiR miR-155-5p and the tumor suppressor-miR miR-203a-3p exhibit an association with STS patient prognosis and are suggested as candidates for risk assessment.

show abstract

Prognostic role of microRNA-155 in patients with leukemia: A meta-analysis

Cited by 13 publications

References 64 publications

miRNA‐155 and miRNA‐181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia

miRNA‐155 and miRNA‐181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia

MicroRNAs in Leukemias: A Clinically Annotated Compendium

MiR-155-5p and MiR-203a-3p Are Prognostic Factors in Soft Tissue Sarcoma

Contact Info

Product

Resources

About